EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Amicus Therapeutics, Inc. (NASDAQ:FOLD) securities between March 19, 2015 and October 1, 2015.
Click here to learn about the case: http://docs.wongesq.com/FOLD-Info-Request-Form-939. There is no cost or obligation to you.
The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose that the United States Food and Drug Administration raised concerns about Amicus Therapeutics’ forthcoming new drug application for migalastat during their September 15, 2015 meeting.
On October 2, 2015, Amicus Therapeutics revealed it would no longer be in a position to submit its NDA in the fourth quarter of 2015. Upon this news, shares of Amicus Therapeutics fell 54% to close at $6.39 per share.
If you suffered a loss in Amicus Therapeutics you have until December 7, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/FOLD-Info-Request-Form-939.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
